Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

URGN

UroGen Pharma Ltd

Nov 28 • 02:58PM ET

12.96

Dollar change +0.18
Percentage change 1.41	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.23	Insider Own	13.05%	Shs Outstand	30.81M	Perf Week	4.26%
Market Cap	399.30M	Forward P/E	-	EPS next Y	-2.59	Insider Trans	-0.09%	Shs Float	26.79M	Perf Month	17.18%
Income	-104.48M	PEG	-	EPS next Q	-0.68	Inst Own	59.51%	Short Float / Ratio	10.55% / 11.43	Perf Quarter	-31.75%
Sales	77.28M	P/S	5.17	EPS this Y	25.59%	Inst Trans	-0.64%	Short Interest	2.83M	Perf Half Y	36.13%
Book/sh	-1.36	P/B	-	EPS next Y	27.33%	ROA	-64.87%	Target Price	39.00	Perf Year	70.75%
Cash/sh	4.81	P/C	2.69	EPS next 5Y	-	ROE	-	52W Range	7.15 - 24.13	Perf YTD	46.11%
Dividend	-	P/FCF	-	EPS past 5Y	-17.60%	ROI	-181.54%	52W High	-46.29%	Beta	0.99
Dividend %	-	Quick Ratio	6.87	Sales past 5Y	13121.31%	Gross Margin	87.92%	52W Low	81.26%	ATR	0.68
Employees	200	Current Ratio	7.06	Sales Q/Q	29.54%	Oper. Margin	-92.15%	RSI (14)	60.05	Volatility	6.18% 5.22%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	40.21%	Profit Margin	-135.20%	Rel Volume	0.46	Prev Close	12.78
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 14 BMO	Payout	-	Avg Volume	247.21K	Price	12.96
Recom	1.40	SMA20	9.44%	SMA50	0.82%	SMA200	3.13%	Volume	96,665	Change	1.41%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-08-23	Downgrade	Jefferies	Buy → Hold	$35 → $10
Apr-27-22	Initiated	Berenberg	Buy	$20
Apr-16-20	Reiterated	H.C. Wainwright	Buy	$53 → $57
Apr-13-20	Reiterated	H.C. Wainwright	Buy	$75 → $53
Jan-09-20	Initiated	National Securities	Neutral	$37
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy	$82
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy	$50
Nov-15-17	Reiterated	Oppenheimer	Outperform	$32 → $51
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Nov-15-23 01:50PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 12:19PM	UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials (GuruFocus.com)
08:00AM	UroGen Pharma Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-13-23 08:00AM	UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology (Business Wire)
Nov-07-23 08:00AM	UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire)
08:00AM	Loading…
Oct-03-23 08:00AM	Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024 (Business Wire)
Sep-11-23 07:00AM	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-08-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Aug-18-23 01:40PM	UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why (Zacks)
Aug-17-23 07:00AM	New Treatment for Bladder Cancer Offers This Biotech a Second Chance (The Wall Street Journal) -14.16%
Aug-12-23 09:18AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:55AM	Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet (Zacks)
09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments (Business Wire)
08:00AM	Loading…
Aug-08-23 08:00AM	The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Aug-02-23 05:00PM	UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (Business Wire) -6.45%
Aug-01-23 10:05AM	Opportunities Outweigh Risks: Oppenheimer Sees at Least 60% Gains in These 2 Stocks (TipRanks) -6.28%
Jul-31-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-23 01:41PM	Why Shares of UroGen Pharma Jumped Friday (Motley Fool) +26.38%
Jul-27-23 09:55AM	UroGen Announces $120 Million Private Placement of Ordinary Shares (Business Wire) +98.56%
09:50AM	UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials (Business Wire)
Jul-25-23 04:10PM	UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors (Business Wire)
Jul-10-23 08:00AM	Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation (Business Wire) -5.28%
Jul-06-23 08:00AM	UroGen Pharma to Host UGN-102 Data Event on July 27, 2023 (Business Wire) +5.08%
Jun-20-23 08:00AM	Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration (Business Wire)
Jun-09-23 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.33%
Jun-02-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
May-22-23 01:18PM	With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
May-16-23 12:13PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript (Insider Monkey)
09:15AM	Loading…
May-11-23 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.00%
08:00AM	UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)
May-04-23 08:00AM	UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023 (Business Wire)
May-02-23 10:02AM	Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline (Zacks) -8.61%
May-01-23 02:00PM	First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation (Business Wire) +23.30%
Apr-30-23 08:00AM	New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis (Business Wire)
Apr-25-23 08:00AM	UroGen Pharma to Present at H.C. Wainwright BioConnect Conference (Business Wire)
Apr-18-23 12:16PM	UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift Shares (Simply Wall St.)
Mar-18-23 02:06AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 09:15AM	Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments (Business Wire)
Mar-09-23 04:00PM	UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023 (Business Wire)
Mar-06-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-01-23 04:00PM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Feb-27-23 08:15AM	Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-15-23 09:06AM	Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer (Business Wire)
Feb-06-23 05:33AM	UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jan-11-23 08:00AM	Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer (Business Wire)
Jan-09-23 12:19PM	The past five years for UroGen Pharma (NASDAQ:URGN) investors has not been profitable (Simply Wall St.)
Dec-19-22 08:00AM	UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
Dec-13-22 12:13PM	With 57% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
Dec-09-22 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-02-22 12:00PM	UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Dec-01-22 07:00PM	UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer (Business Wire)
Nov-21-22 04:00PM	UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference (Business Wire) -7.51%
Nov-16-22 11:24AM	Some Analysts Just Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Estimates (Simply Wall St.)
Nov-14-22 08:00AM	UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma (Business Wire)
Nov-12-22 07:33AM	UroGen Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-10-22 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -16.32%
08:00AM	UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (Business Wire)
Nov-09-22 08:00AM	UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors (Business Wire) -7.66%
Nov-03-22 08:00AM	UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022 (Business Wire)
Oct-12-22 04:29AM	Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.22%
Oct-11-22 11:54AM	10 Best Immunotherapy Stocks To Buy Now (Insider Monkey)
08:00AM	UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers (Business Wire)
Sep-28-22 08:00AM	FDA Authorizes an Extension of the In-Use Period for UroGen Pharmas JELMYTO® Admixture to 96 Hours Following Reconstitution (Business Wire) +7.58%
Sep-12-22 08:00AM	UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors (Business Wire) +5.70%
Sep-09-22 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-07-22 04:00PM	UroGen Pharma Announces Upcoming 2022 Conferences (Business Wire)
Aug-11-22 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.51%
08:00AM	UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (Business Wire)
Jul-27-22 08:00AM	UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022 (Business Wire)
Jul-24-22 09:56AM	UroGen Pharma (NASDAQ:URGN) shareholders have endured a 73% loss from investing in the stock three years ago (Simply Wall St.)
Jul-12-22 09:05AM	10 Micro-Cap Stocks To Buy According To Cathie Wood (Insider Monkey)
Jun-09-22 09:07AM	Do Institutions Own UroGen Pharma Ltd. (NASDAQ:URGN) Shares? (Simply Wall St.)
Jun-03-22 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.58%
May-18-22 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire) -5.95%
May-16-22 02:50PM	UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer (Business Wire) -6.05%
May-13-22 08:00AM	UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting (Business Wire)
May-10-22 10:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.97%
09:00AM	UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments (Business Wire)
08:00AM	Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates (GlobeNewswire)
May-09-22 06:15PM	Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-05-22 06:35PM	Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.54%
May-03-22 08:00AM	UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022 (Business Wire)
Mar-29-22 08:00AM	UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer (Business Wire) +7.23%
Mar-22-22 08:02AM	Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer (GlobeNewswire)
Mar-21-22 09:15AM	Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments (Business Wire)
Mar-08-22 08:00AM	UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven (Business Wire) +23.31%
Mar-04-22 04:30PM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
03:00PM	UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022 (Business Wire)
Mar-03-22 08:25AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-01-22 08:15AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer (Business Wire)
Feb-28-22 08:00AM	UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference (Business Wire)
Feb-24-22 05:40PM	Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-10-22 08:00AM	UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients (Business Wire)
Feb-03-22 08:00AM	UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Jan-18-22 01:38PM	HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ... (GuruFocus.com) -5.30%

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Jason Drew	General Counsel	Aug 31	Sale	18.01	3,800	68,438	18,407	Sep 05 04:28 PM
Schoenberg Mark	Chief Medical Officer	Jan 31	Sale	10.12	1,900	19,228	146,879	Feb 02 01:02 PM
Smith Jason Drew	General Counsel	Jan 31	Sale	10.12	1,636	16,556	12,600	Feb 02 01:04 PM
Schoenberg Mark	Chief Medical Officer	Jan 20	Option Exercise	5.00	122,677	613,385	146,627	Jan 23 07:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

URGN

UroGen Pharma Ltd

Upgrade your FINVIZ experience